Gene therapy for the treatment of cystic fibrosis

Application of Clinical Genetics

Volumn 5, Issue , 2012, Pages 29-36

  Burney, Tabinda J ^a,b   Davies, Jane C ^a,b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UK CF Gene Therapy Consortium London ^*  (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cystic fibrosis transmembrane conductance regulator (CFTR) gene; Gene expression; Gene transfer agents (GTAs); Outcome measures

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 3BETA [N (N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; ADENOVIRUS VECTOR; CHLORIDE; CHOLESTEROL DERIVATIVE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; IVACAFTOR; LENTIVIRUS VECTOR; LIPOSOME; MACROGOL; PARVOVIRUS VECTOR; SODIUM; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

BRONCHUS MUCOSA; CFTR GENE; CHLORIDE TRANSPORT; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; GENE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; IN VITRO STUDY; MEDICAL SOCIETY; MOLECULAR CLONING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NOSE MUCOSA; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; REVIEW; SODIUM TRANSPORT; TRANSLATIONAL RESEARCH; UNITED KINGDOM; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA;

EID: 84930484192     PISSN: 1178704X     EISSN: None     Source Type: Journal    
DOI: 10.2147/TACG.S8873     Document Type: Review

References (56)

1. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-1254.
2. Cystic Fibrosis Foundation. Patient Registry: Annual Data Report 2010. Bethesda, MD: Cystic Fibrosis Foundation; 2010.
3. Tarran R, Button B, Picher M, etal. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem. 2005;280(42):35751-35759.
4. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med. 2002;165(7):911-915.
5. Karp CL, Flick LM, Park KW, etal. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004;5(4):388-392.
6. Hartl D, Griese M, Kappler M, etal. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol. 2006;117(1):204-211.
7. Ashlock MA, Olson ER. Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease. Annu Rev Med. 2011;62:107-125.
8. Kitson C, Angel B, Judd D, etal. The extra-and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther. 1999;6(4):534-546.
9. Zabner J, Ramsay BW, Meeker DP, etal. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest. 1996;97(6):1504-1511.
10. Schwarzt DA, Quinn TJ, Thorne PS, Sayeed S, Yi AK, Krieg AM. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest. 1997;100(1):68-73.
11. Crystal RG, McElvaney NG, Rosenfeld MA, etal. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Gene. 1994;8(1):42-51.
12. Walters RW, Grunst T, Bergelson JM, etal. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem. 1999;274(15):10219-10226.
13. Parsons DW, Grubb BR, Johnson LG, Boucher RC. Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent. Hum Gene Ther. 1998;9(18):2661-2272.
14. Weiss DJ, Beckett T, Bonneau L, Young J, Kolls JK, Wang G. Transient increase in lung epithelial tight junction permeability: an additional mechanism for enhancement of lung transgene expression by perfluorochemical liquids. Mol Ther. 2003;8(6):927-935.
15. Zhang L, Wang D, Fischer H, etal. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc Natl Acad Sci U S A. 1998;95(17):10158-10163.
16. Song Y, Lou HH, Boyer JL, etal. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. Hum Gene Ther. 2009;20(3):267-281.
17. Ferrari S, Griesenbach U, Iida A, et al. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther. 2007;14:1371-1379.
18. Bishop AE. Pulmonary epithelial stem cells. Cell Prolif. 2004;37(1): 89-96.
19. Hacein-Bey-Abina S, Garrigue A, Wang GP, etal. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142.
20. Johnson LG, Olsen JC, Naldini L, Boucher RC. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. 2000;7(7):568-574.
21. Griesenbach U, Ferrari S, Geddes DM, Alton EWFW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 2002;9(20): 1344-1350.
22. Delenda C. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med. 2004;6 Suppl 1:S125-S138.
23. Mitomo K, Griesenbach U, Inoue M, etal. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther. 2010;18(6):1173-1182.
24. Hyde SC, Pringle IA, Abdullah S, etal. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26(5):549-551.
25. Engelhardt JF, Yankaskas JR, Ernst SA, etal. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet. 1992;2(3):240-248.
26. Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, Wilson JM. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest. 1994;93(2):737-749.
27. Sinn PL, Anthony RM, McCray PB Jr. Genetic therapies for cystic fibrosis lung disease. Hum Mol Genet. 2011;20(R1):R79-R86.
28. Davies JC, Alton EW. Gene therapy for cystic fibrosis. Proc Am Thorac Soc. 2010;7(6):408-414.
29. Griesenbach U, Smith SN, Farley R, Singh C, Alton EW. Validation of nasal potential difference measurements in gut-corrected CF knockout mice. Am J Respir Cell Mol Biol. 2008;39(4):490-496.
30. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther. 1995;6(4):445-455.
31. Accurso FJ, Rowe SM, Clancy JP, etal. Effect of VX-770in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991-2003.
32. Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest. 1995;95(3):1377-1382.
33. Bronsveld I, Mekus F, Bijman J, etal. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest. 2001;108(11): 1705-1715.
34. Simmonds NJ, D'Souza L, Roughton M, Alton EW, Davies JC, Hodson ME. Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function. Eur Respir J. 2011;37(5):1076-1082.
35. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 1993;75(2):207-216.
36. Knowles MR, Hohneker KW, Zhou Z, etal. A controlled study of adenoviral-vector mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med. 1995;333(13):823-831.
37. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther. 1995;6(11):1487-1496.
38. Bellon G, Michel-Calemard L, Thouvenot D, etal. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther. 1997;8(1):15-25.
39. Harvey BG, Leopold PL, Hackett NR, etal. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest. 1999;104(9):1245-1255.
40. Zuckerman JB, Robinson CB, McCoy KS, etal. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999;10(18):2973-2985.
41. Joseph PM, O'Sullivan BP, Lapey A, etal. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther. 2001; 12(11):1369-1382.
42. Perricone MA, Morris JE, Pavelka K, etal. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther. 2001; 12(11):1383-1394.
43. Wagner JA, Messner AH, Moran ML, etal. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope. 1999;109(2 Pt 1):266-274.
44. Aitken ML, Moss RB, Waltz DA, etal. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther. 2001;12(15):1907-1916.
45. Wagner JA, Nepomuceno IB, Messner AH, etal. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther. 2002;13(11):1349-1359.
46. Flotte TR, Zeitlin PL, Reynolds TC, etal. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther. 2003;14(11):1079-1088.
47. Moss RB, Rodman D, Spencer LT, etal. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125(2):509-521.
48. Moss RB, Milla C, Colombo J, etal. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007;18(8):726-732.
49. Caplen NJ, Alton EW, Middleton PG, etal. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1995;1(1):39-46.
50. Gill DR, Southern KW, Mofford KA, etal. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997;4(3):199-209.
51. Porteous DJ, Dorin JR, McLachlan G, etal. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997; 4(3):210-218.
52. Hyde SC, Southern KW, Gileadi U, etal. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 2000;7(13):1156-1165.
53. Zabner J, Cheng SH, Meeker D, etal. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest. 1997;100(6):1529-1537.
54. Alton EW, Stern M, Farley R, etal. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999;353(9157):947-954.
55. Ruiz FE, Clancy JP, Perricone MA, etal. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther. 2001;12(7):751-761.
56. Konstan MW, Davis PB, Wagener JS, etal. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther. 2004;15(12): 1255-1269.